Exploring Epigenetics in AML Oncogenesis
Chapter 1: Exploring Epigenetics in AML: DNA Methylation
Editor’s Note: Following the release of this activity, on August 1, 2017 the FDA granted regular approval to enasidenib (AG-221) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Please complete Pre-test
Chapter 1 of 2
Release Date: June 23, 2017
Expiration Date: June 23, 2018
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
In acute myeloid leukemia (AML), several epigenetic pathways have been implicated in disease pathogenesis, including DNA methylation, histone acetylation, and histone methylation. Ongoing research is focusing on these epigenetic pathways for the development of novel agents and regimens across the disease lifecycle. Join Dr. Ravandi-Kashani as he describes the molecular and cellular processes that are driving oncogenesis in AML, how the mechanisms of action of several new and emerging agents in AML target specific genetic mutations, and the critical implications for clinical practice.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Identify the various epigenetic pathways for AML oncogenesis
- Describe current trials and best practices focusing on epigenetic therapies that will support improved outcomes in patients with AML
Exploring Epigenetics in AML Oncogenesis – Farhad Ravandi-Kashani, MD
Instructions for Participation and Credit
This activity is eligible for credit through June 23, 2018. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Farhad Ravandi-Kashani, MD
Professor, Department of Leukemia
Division of Cancer Medicine
Chief, Section of Developmental Therapeutics
The University of Texas MD Anderson Cancer Center
Dr. Farhad Ravandi-Kashani received his medical degree from St. Mary's Hospital Medical School/Imperial College, University of London. He completed clinical residencies in internal medicine at The University of Texas, and in hematology at Baylor College of Medicine. He also completed a clinical fellowship in hematology/oncology, and a fellowship in blood and marrow transplantation, hematology/stem cell transplantation at The University of Texas MD Anderson Cancer Center. Dr. Ravandi-Kashani is a Professor in the Department of Leukemia, Division of Cancer Medicine, and Chief, Section of Developmental Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Ravandi-Kashani holds board certification in internal medicine, medical oncology, and hematology. He is a member of the Southwest Oncology Group Leukemia Committee, the NCCN Acute Myeloid Leukemia Committee, the International Hairy Cell Leukemia Consortium, and the Cancer and Leukemia Group B Data Safety Monitoring Board. Dr. Ravandi-Kashani is actively involved in clinical and translational research for the treatment of patients with various hematologic malignancies, in particular leukemias. He has extensively published his clinical research results in the field of adult leukemias, with a focus on acute leukemias in numerous peer-reviewed publications, articles, editorials, abstracts, and books/book chapters.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-153-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Farhad Ravandi-Kashani has received honoraria related to formal advisory activities and grant support related to research activities from Amgen Inc., Seattle Genetics, Inc., Sunesis Pharmaceuticals, Inc., and Xencor, in addition to grant support related to research activities from Bristol-Myers Squibb Company and Selvita.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.